Immunotech Biopharm Ltd (6978.HK)
- Previous Close
3.370 - Open
3.490 - Bid 3.580 x --
- Ask 3.580 x --
- Day's Range
3.490 - 3.490 - 52 Week Range
3.020 - 5.000 - Volume
2,000 - Avg. Volume
39,289 - Market Cap (intraday)
1.842B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.700 - Earnings Date Mar 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
www.eaal.netRelated News
Performance Overview: 6978.HK
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6978.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6978.HK
Valuation Measures
Market Cap
1.73B
Enterprise Value
2.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
9.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.23
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.74%
Return on Equity (ttm)
-99.07%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-334.82M
Diluted EPS (ttm)
-0.700
Balance Sheet and Cash Flow
Total Cash (mrq)
176.97M
Total Debt/Equity (mrq)
267.53%
Levered Free Cash Flow (ttm)
--
Company Insights: 6978.HK
6978.HK does not have Company Insights